过去一年中添加的文章，按日期排序
Mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations
K Pan, J Owens, Y Elamin, C Lu, M Routbort… - Journal of Thoracic …, 2024 - Elsevier
11 天前 - … , with EGFR T790M being a known germline mutation identified in … Results We
identified 22 patients with germline EGFR mutations, with the majority harboring an EGFR T790M …
identified 22 patients with germline EGFR mutations, with the majority harboring an EGFR T790M …
Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine …
J Lee, H Lee, D Yoon, EY Choi, J Woo, B Jo, S Kim… - Cancers, 2024 - mdpi.com
15 天前 - … T790M-positive and T790M-negative NSCLC patients after EGFR-TKI failure showed
no differences in clinical outcome … T790M mutation status on the basis that EGFR T790M …
no differences in clinical outcome … T790M mutation status on the basis that EGFR T790M …
… and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell …
S Park, R Baldry, HA Jung, JM Sun, SH Lee… - Journal of Clinical …, 2024 - ascopubs.org
18 天前 - … EGFR T790M mutation (18.8 months) showed similar OS to patients with EGFR
T790M mutation (… In line with our results, a preclinical study demonstrates that osimertinib was …
T790M mutation (… In line with our results, a preclinical study demonstrates that osimertinib was …
Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma
XL Ma, RN Jia, K Han, YX Zhang - Zhonghua Bing li xue za zhi …, 2024 - europepmc.org
21 天前 - … the main mutation sites in IMA and INMA, with a higher mutation rate at exon 20
T790M (11.63%) … In IMA, KRAS had the highest overall mutation rate (43.80%), with statistically …
T790M (11.63%) … In IMA, KRAS had the highest overall mutation rate (43.80%), with statistically …
… study of 80 mg osimertinib in patients with leptomeningeal metastases (LM) associated with epidermal growth factor receptor (EGFR) mutation–positive non-small cell …
MJ Ahn, S Park, R Baldry, HA Jung, JM Sun, SH Lee… - 2024 - ascopubs.org
24 天前 - … Results: Out of 73 patients administered 80mg osimertinib, 64 were evaluated for LM
… mutated LM regardless of T790M mutation status. Clinical trial information: NCT04563871. …
… mutated LM regardless of T790M mutation status. Clinical trial information: NCT04563871. …
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA …
T John, C Grohe, JW Goldman, T Kato, KK Laktionov… - 2024 - ascopubs.org
24 天前 - … T790M resistance mutations. Adj osi (3 years [yrs]) is recommended for resected
EGFRm stage IB–IIIA NSCLC, based on significant improvements in disease-free survival (DFS…
EGFRm stage IB–IIIA NSCLC, based on significant improvements in disease-free survival (DFS…
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
S Zhao, H Zhao, L Zhang, Y Sun, W Zhuang, X Dong… - 2024 - ascopubs.org
24 天前 - 8077 Background: ARUKA has been implicated in the emergence of resistance to
osimertinib. VIC-1911 is a highly selective ARUKA inhibitor that has minimal activity in EGFR-…
osimertinib. VIC-1911 is a highly selective ARUKA inhibitor that has minimal activity in EGFR-…
… switching to osimertinib (A) versus osimertinib alone (B) as first-line treatment in advanced NSCLC patients with common EGFR mutation: YAMATO study (TORG1939 …
A Nakamura, H Yoshioka, T Misumi, T Yokoyama… - 2024 - ascopubs.org
24 天前 - … Background: NSCLC with common EGFR mutation (L858R or exon 19 … T790M-mutant
ones albeit treatment-naïve. To overcome concomitant heterogeneous EGFR mutations, …
ones albeit treatment-naïve. To overcome concomitant heterogeneous EGFR mutations, …
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
J N. Priantti, M Vilbert, FCA Moraes… - Journal of Clinical …, 2024 - ascopubs.org
24 天前 - … mutations were defined as any mutation other than the exon 19 deletion, L858R
and T790M mutations, … Results: Nine studies comprising 331 patients were included. Median …
and T790M mutations, … Results: Nine studies comprising 331 patients were included. Median …
… prognostic factors in small cell lung cancer transformation of advanced non-small cell lung cancer with epidermal growth factor receptor mutation after tyrosine kinase …
YT Liao, CL Chiang, RL Sun, Y Yeh, HC Huang… - 2024 - ascopubs.org
24 天前 - … analysis was performed in 68.3% of the tSCLC specimen, and acquired T790M …
mutation after TKI therapy is associated with diverse clinical characteristics and dismal outcomes…
mutation after TKI therapy is associated with diverse clinical characteristics and dismal outcomes…